News

Tiny Protein Packages Released from Cells May Serve as Biomarkers for Early Blood-Based Cancer Diagnosis

Tiny packets called extracellular vesicles and particles (EVPs), released by cancer and immune cells, contain specific proteins that may serve as reliable biomarkers for diagnosing early-stage cancer, according to investigators at Weill Cornell Medicine and Memorial Sloan Kettering. A new study published August 13 in Cell identifies new biomarkers in EVPs that can be used to help discriminate these … Continued

Read More

PRESS RELEASE: THE PERSHING SQUARE SOHN CANCER RESEARCH ALLIANCE AWARDS $4.2M TO SEVEN RISING LEADERS IN CANCER RESEARCH

THE PERSHING SQUARE SOHN CANCER RESEARCH ALLIANCE AWARDS $4.2M TO SEVEN RISING LEADERS IN CANCER RESEARCH The Pershing Square Sohn Prize Has Supported 46 Cancer Scientists in the New York Life Science Ecosystem by Funding High-Risk, High-Reward Research NEW YORK, JULY 29, 2020 (Business Wire) – The Pershing Square Sohn Cancer Research Alliance today announced … Continued

Read More

The first mouse model of human pancreas cancer subtypes

Scientists at Cold Spring Harbor Laboratory (CSHL) have created the first mouse model of pancreatic cancer that recreates two subtypes of the human disease. The model, published July 23, 2020 in Cancer Discovery, will help researchers investigate why some pancreatic cancers are more aggressive than others and what causes them to progress, paving the way to … Continued

Read More

A Wisconsin City Experiments With a Faster, DIY Covid-19 Test

In a former boxing gym in Racine, firefighters are trying out a spit test that’s simpler and cheaper than PCR. Could it change how we screen for the virus? EACH MORNING AT 7, Brian Wolf, the fire chief of Racine, Wisconsin, arrives for work in a neglected corner of a building called the City Hall … Continued

Read More

PRESS RELEASE: THE PERSHING SQUARE FOUNDATION AWARDS $3 MILLION TO INNOVATIVE SARS-COV-2 RESEARCH PROJECTS

THE PERSHING SQUARE FOUNDATION AWARDS $3 MILLION TO INNOVATIVE SARS-COV-2 RESEARCH PROJECTS Foundation Supports Leaders in Life Science who have Refocused Work to Combat the Coronavirus Pandemic NEW YORK, July 7, 2020 (Businesswire) – The Pershing Square Foundation (the “Foundation”) today announced that it has awarded $3 million to nineteen recipients at ten academic research institutions … Continued

Read More

Why pancreatic ductal adenocarcinoma is so lethal

Pancreatic ductal adenocarcinoma (PDA) is a deadly cancer, killing patients within a year. CSHL Professor Christopher Vakoc and his former postdoc Timothy Somerville discovered how pancreatic cells lose their identity, acquire a deadly new identity, and recruit nearby cells to help them grow, promote inflammation, and invade nearby tissues. This understanding could lead to new … Continued

Read More

Microbe Mappers Are Tracking Covid-19’s Invisible Traces

DURING THE SECOND week of March, as the World Health Organization declared Covid-19 a global pandemic, a team of latex-gloved scientists from Cornell Weill Medical School fanned out across Penn Station armed with packs of sterile, long-armed swabs and a tripod-mounted instrument for capturing air samples. In New York City, the 100th person had just tested positive … Continued

Read More

‘Spider-Man’ Immune Response May Promote Severe COVID-19

A menagerie of immune cells and proteins defend the human body, and a relatively obscure member of this crew is getting new attention as a possible target for treating COVID-19. Neutrophils make up more than half of our white blood cells and are often the first to arrive at the scene of infection. But historically … Continued

Read More

What Does Cancer Metastasis Have to Do with Wound Healing? More than You Might Think

Read More

How pancreatic RAS tumors protect themselves. Researchers point to a new protein — and maybe a new treatment

A couple years back, some cardiovascular specialists at Boston’s Brigham and Women’s Hospital stumbled across a surprising result. Novartis had tasked them with carrying out the long-range Phase III trial for canakinumab, an experimental anti-inflammatory drug the company was trying to market for cardiovascular disease. The main results were mixed — modest reductions in fatal … Continued

Read More